Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIMD NASDAQ:CALC NASDAQ:LPCN NASDAQ:TENK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMDAinos$1.92$1.83$1.26▼$4.50$16.36M2.41548,264 shs19,255 shsCALCCalciMedica$0.89+0.3%$0.68$0.46▼$7.20$14.11M0.97789,018 shs70,823 shsLPCNLipocine$2.30+4.3%$2.40$1.81▼$12.37$18.91M0.48283,111 shs169,464 shsTENKTenX Keane Acquisition$0.64-3.3%$12.88$9.54▼$49.00$4.27MN/A65,453 shs272,302 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMDAinos+1.59%-13.90%+14.29%+36.17%-30.94%CALCCalciMedica-4.29%+3.66%+41.46%+7.41%-50.75%LPCNLipocine+10.10%-1.36%-6.44%-70.30%-33.94%TENKTenX Keane Acquisition0.00%0.00%0.00%-29.43%-49.83%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMDAinos$1.92$1.83$1.26▼$4.50$16.36M2.41548,264 shs19,255 shsCALCCalciMedica$0.89+0.3%$0.68$0.46▼$7.20$14.11M0.97789,018 shs70,823 shsLPCNLipocine$2.30+4.3%$2.40$1.81▼$12.37$18.91M0.48283,111 shs169,464 shsTENKTenX Keane Acquisition$0.64-3.3%$12.88$9.54▼$49.00$4.27MN/A65,453 shs272,302 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMDAinos+1.59%-13.90%+14.29%+36.17%-30.94%CALCCalciMedica-4.29%+3.66%+41.46%+7.41%-50.75%LPCNLipocine+10.10%-1.36%-6.44%-70.30%-33.94%TENKTenX Keane Acquisition0.00%0.00%0.00%-29.43%-49.83%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMDAinos 1.00SellN/AN/ACALCCalciMedica 2.00Hold$10.001,008.65% UpsideLPCNLipocine 2.33Hold$15.00557.89% UpsideTENKTenX Keane Acquisition 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TENK, LPCN, CALC, and AIMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/26/2026AIMDAinos Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/8/2026AIMDAinos Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/6/2026LPCNLipocine HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral3/27/2026LPCNLipocine Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMDAinos$120K133.48N/AN/A$1.29 per share1.46CALCCalciMedicaN/AN/AN/AN/A($0.46) per shareN/ALPCNLipocine$1.98M9.49N/AN/A$2.61 per share0.87TENKTenX Keane AcquisitionN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMDAinos-$14.77M-$2.89N/AN/AN/A-11,912.10%-160.55%-62.29%N/ACALCCalciMedica-$29.56M-$1.31N/AN/AN/AN/A-863.40%-144.33%8/11/2026 (Estimated)LPCNLipocine-$9.63M-$1.88N/AN/AN/A-571.18%-66.70%-59.39%8/4/2026 (Estimated)TENKTenX Keane AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AN/ALatest TENK, LPCN, CALC, and AIMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026AIMDAinosN/A-$0.41N/A-$0.41N/AN/A5/7/2026Q1 2026LPCNLipocine-$0.51-$0.54-$0.03-$0.54$0.16 million$0.12 million3/30/2026Q4 2025AIMDAinosN/A-$0.85N/A-$0.85N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAIMDAinosN/AN/AN/AN/AN/ACALCCalciMedicaN/AN/AN/AN/AN/ALPCNLipocineN/AN/AN/AN/AN/ATENKTenX Keane AcquisitionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMDAinos1.580.550.50CALCCalciMedicaN/A1.611.61LPCNLipocineN/A9.999.99TENKTenX Keane AcquisitionN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMDAinosN/ACALCCalciMedicaN/ALPCNLipocine9.11%TENKTenX Keane Acquisition70.52%Insider OwnershipCompanyInsider OwnershipAIMDAinos9.79%CALCCalciMedica41.55%LPCNLipocine6.35%TENKTenX Keane Acquisition22.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMDAinos408.52 million7.69 millionNot OptionableCALCCalciMedica3015.80 million9.23 millionNo DataLPCNLipocine108.24 million7.72 millionNo DataTENKTenX Keane AcquisitionN/A6.65 million5.13 millionNot OptionableTENK, LPCN, CALC, and AIMD HeadlinesRecent News About These CompaniesCTOR stock touches 52-week low at $0.9 amid market challengesNovember 24, 2024 | investing.comHow to Complete On This Day Robbie KeaneNovember 6, 2024 | ign.comICitius Oncology Inc (CTOR)October 17, 2024 | investing.comCitius Pharmaceuticals, Inc.: Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.August 14, 2024 | finanznachrichten.deCitius Pharmaceuticals, Inc.: Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.August 6, 2024 | finanznachrichten.deTenX Keane Acquisition Shares Rise After Merger ApprovalAugust 5, 2024 | marketwatch.comCitius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business UpdateFebruary 14, 2024 | finance.yahoo.comTenX Keane Acquisition Announces Contribution to Trust Account in Connection with Extension Amendment ProposalJanuary 10, 2024 | finance.yahoo.comTenX Keane Acquisition (TENK)October 31, 2023 | investing.comCitius unit to merge with TenX Keane to form public companyOctober 26, 2023 | msn.comMatthew G. KeaneAugust 23, 2023 | health.usnews.comTenX Keane Acquisition to extend date for completion of business combinationJuly 18, 2023 | seekingalpha.comTenX Keane Acquisition Announces Extension of the Deadline for an Initial Business CombinationJuly 18, 2023 | finance.yahoo.comUncertainty Returns After BitGo Cancels Prime Trust AcquisitionJuly 8, 2023 | bitcoinmagazine.comRoy Keane outlines his "worry" for Man Utd ahead of FA Cup final vs Man CityJune 26, 2023 | mirror.co.ukMPAY/BTC - TenX BitcoinMay 13, 2023 | investing.comMargaret KeaneApril 27, 2023 | mutualart.comMEpiphany Technology Acquisition Corp Ordinary Shares - Class AJanuary 6, 2023 | morningstar.comMFigure Acquisition Corp I - Ordinary Shares - Class ADecember 14, 2022 | money.usnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTENK, LPCN, CALC, and AIMD Company DescriptionsAinos NASDAQ:AIMD$1.92 0.00 (0.00%) As of 03:40 PM Eastern This is a fair market value price provided by Massive. Learn more.Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.CalciMedica NASDAQ:CALC$0.89 +0.00 (+0.28%) As of 03:41 PM Eastern This is a fair market value price provided by Massive. Learn more.CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.Lipocine NASDAQ:LPCN$2.30 +0.10 (+4.32%) As of 03:40 PM Eastern This is a fair market value price provided by Massive. Learn more.Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.TenX Keane Acquisition NASDAQ:TENKTenX Keane Acquisition does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on target businesses operating in Asia, excluding companies located or operating in mainland China, Hong Kong, or Macau. TenX Keane Acquisition was incorporated in 2021 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Microsoft Just Gave Investors 3 Dates They Can't Afford to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
